Efficacy of Acupuncture for Primary Insomnia: A Randomized Controlled Clinical Trial

Table 2

Change in SF-36 (Mean ± SD) from baseline to 2-month follow-up.

Item  timepoint	Verum  group	Estazolam  group	Sham  group	𝑃
				Verum versus sham	Verum versus estazolam	Estazolam versus sham
PF
Baseline	85.6±10.8	88.1±8.3	86.4±10.4
Week 6	88.4±9.6	89.8±6.4	87.7±8.5	0.68	0.35	0.18
2-month follow-up	89.8±7.7	87.9±8.3	86.6±9.1	0.05	0.24	0.42
RP
Baseline	53.5±10.0	55.1±13.5	56.3±10.9
Week 6	63.1±12.5^∗	64.2±13.4^∗	59.7±13.3	0.18	0.63	0.07
2-month follow-up	61.4±14.3^∗	58.5±16.7	57.2±13.4	0.15	0.31	0.66
BP
Baseline	84.7±12.9	87.1±8.0	85.3±10.0
Week 6	87.0±13.6	89.7±10.1	86.6±11.3	0.85	0.24	0.18
2-month follow-up	86.3±15.8	87.7±13.8	83.5±13.2	0.30	0.63	0.13
GH
Baseline	35.7±10.1	36.1±8.6	33.2±6.9
Week 6	38.0±10.2	36.0±10.9	34.7±10.6	0.11	0.31	0.53
2-month follow-up	36.6±8.6	34.5±10.7	33.8±8.1	0.11	0.21	0.69
VT
Baseline	36.8±9.4	33.6±9.9	34.4±7.1
Week 6	44.6±13.1^∗	32.1±10.1	37.7±10.5	0.002	<0.001	0.01
2-month follow-up	42.3±12.0^∗	32.1±8.5	35.4±10.0	0.001	<0.001	0.10
SF
Baseline	73.6±12.0	75.6±9.7	72.1±10.4
Week 6	81.6±11.5^∗	80.7±17.0^∗	74.4±15.7	0.02	0.75	0.03
2-month follow-up	76.3±13.9	77.9±15.6	73.0±13.0	0.24	0.56	0.08
RE
Baseline	31.3±7.7	33.4±6.3	32.3±9.0
Week 6	37.4±19.5^∗	42.1±16.5^∗	33.8±17.0^∗	0.29	0.16	0.02
2-month follow-up	38.0±16.4^∗	34.3±14.3	31.8±16.2	0.04	0.21	0.42
MH
Baseline	48.1±19.0	41.1±18.4	47.5±13.2
Week 6	52.2±17.9	54.3±20.8^∗	48.6±17.2	0.32	0.56	0.12
2-month follow-up	50.0±19.3	48.6±19.9	44.7±14.6	0.14	0.70	0.27

SF-36: 36-item short-form health survey; MH: mental health; PF: physical functioning; RP: role-physical; BP: bodily pain; VT: vitality; GH: general health; SF: social functioning; RE: role-emotional.
Data from multivariate analysis of variance (MANOVA) and repeated measures. (Mauchly’s test of sphericity: 𝑃<0.05.) *Comparison within each group with baseline 𝑃<0.05.